Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Claudio A. Schioppa"'
Autor:
Nicolas Girard, Keunchil Park, Se-Hoon Lee, Santiago Viteri, Claudio A. Schioppa, Joris Diels, Mustafa Oguz, Bernardo H. Rodrigues, Nora Rahhali, Jan Sermon, Francesca Ghilotti, Tracy Li, Meena Thayu, Roland E. Knoblauch, Parthiv Mahadevia, Byoung Chul Cho
Publikováno v:
Cancer Treatment and Research Communications, Vol 40, Iss , Pp 100832- (2024)
Background: Amivantamab, an EGFR-MET bispecific antibody, is the first approved targeted therapy for patients with EGFR Ex20ins NSCLC after prior platinum-based chemotherapy—a population with historically poor outcomes before amivantamab approval.
Externí odkaz:
https://doaj.org/article/b0e636fa219d41078d74b8b155ecc004
Autor:
Christos Chouaid, Lise Bosquet, Nicolas Girard, Anna Kron, Matthias Scheffler, Frank Griesinger, Martin Sebastian, Jose Trigo, Santiago Viteri, Craig Knott, Bernardo Rodrigues, Nora Rahhali, Jedelyn Cabrieto, Joris Diels, Nolen J. Perualila, Claudio A. Schioppa, Jan Sermon, Raphael Toueg, Nicole Erdmann, Janka Mielke, Mehregan Nematian-Samani, Cristina Martin-Fernandez, Innocent Pfaira, Tracy Li, Parthiv Mahadevia, Jürgen Wolf
Publikováno v:
Advances in Therapy. 40:1187-1203
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::23cfc7ed40547a3fcabc749e31bc908c
https://doi.org/10.1007/s12325-022-02408-7
https://doi.org/10.1007/s12325-022-02408-7
Autor:
Andrea Papadia, Claudio A. Schioppa
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ba0ad240147865401c8361979ebf845
https://doi.org/10.2139/ssrn.4020237
https://doi.org/10.2139/ssrn.4020237